Review



dfmo eflornithine  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    MedChemExpress dfmo eflornithine
    (A) SK-N-BE(2)-c cells were treated with five doses of QW-5–70 (0.125 to 2 nM) in combination with five doses of <t>DFMO</t> (10–1000 μM). Cell viability was assessed using the MTS assay (n=4). (B) CI–Fa analysis of the QW-5–70 and DFMO combination. CI values were calculated using the Chou–Talalay median-effect method for five experimentally tested dose pairs at their corresponding Fa values. CI < 1, CI = 1, and CI > 1 indicate synergistic, additive, and antagonistic interactions, respectively. (C) SK-N-BE(2)-c cells were treated with five doses of QW-5–70 (0.125 to 2 nM) in combination with five doses of MLN8237 (1–100 nM). Cell viability was assessed using the MTS assay (n=4). (D) SK-N-BE(2)-C cells were treated with 1 nM QW-5–70 in combination with either DFMO (300 μM, top) or MLN8237 (30 nM, bottom) as indicated. Cell lysates were analyzed by immunoblotting for cPARP as a marker of apoptosis, with GAPDH used as a loading control. (E) Representative colony formation images of SK-N-BE(2)-C cells treated with the same combination. Colony formations were quantified and expressed as mean ± SEM relative to vehicle (set to 100%) (n=5).
    Dfmo Eflornithine, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dfmo eflornithine/product/MedChemExpress
    Average 93 stars, based on 13 article reviews
    dfmo eflornithine - by Bioz Stars, 2026-05
    93/100 stars

    Images

    1) Product Images from "QW-5-70 targets the colchicine site and demonstrates antitumor activity in P-gp–overexpressing cancer models"

    Article Title: QW-5-70 targets the colchicine site and demonstrates antitumor activity in P-gp–overexpressing cancer models

    Journal: Molecular cancer therapeutics

    doi: 10.1158/1535-7163.MCT-25-1013

    (A) SK-N-BE(2)-c cells were treated with five doses of QW-5–70 (0.125 to 2 nM) in combination with five doses of DFMO (10–1000 μM). Cell viability was assessed using the MTS assay (n=4). (B) CI–Fa analysis of the QW-5–70 and DFMO combination. CI values were calculated using the Chou–Talalay median-effect method for five experimentally tested dose pairs at their corresponding Fa values. CI < 1, CI = 1, and CI > 1 indicate synergistic, additive, and antagonistic interactions, respectively. (C) SK-N-BE(2)-c cells were treated with five doses of QW-5–70 (0.125 to 2 nM) in combination with five doses of MLN8237 (1–100 nM). Cell viability was assessed using the MTS assay (n=4). (D) SK-N-BE(2)-C cells were treated with 1 nM QW-5–70 in combination with either DFMO (300 μM, top) or MLN8237 (30 nM, bottom) as indicated. Cell lysates were analyzed by immunoblotting for cPARP as a marker of apoptosis, with GAPDH used as a loading control. (E) Representative colony formation images of SK-N-BE(2)-C cells treated with the same combination. Colony formations were quantified and expressed as mean ± SEM relative to vehicle (set to 100%) (n=5).
    Figure Legend Snippet: (A) SK-N-BE(2)-c cells were treated with five doses of QW-5–70 (0.125 to 2 nM) in combination with five doses of DFMO (10–1000 μM). Cell viability was assessed using the MTS assay (n=4). (B) CI–Fa analysis of the QW-5–70 and DFMO combination. CI values were calculated using the Chou–Talalay median-effect method for five experimentally tested dose pairs at their corresponding Fa values. CI < 1, CI = 1, and CI > 1 indicate synergistic, additive, and antagonistic interactions, respectively. (C) SK-N-BE(2)-c cells were treated with five doses of QW-5–70 (0.125 to 2 nM) in combination with five doses of MLN8237 (1–100 nM). Cell viability was assessed using the MTS assay (n=4). (D) SK-N-BE(2)-C cells were treated with 1 nM QW-5–70 in combination with either DFMO (300 μM, top) or MLN8237 (30 nM, bottom) as indicated. Cell lysates were analyzed by immunoblotting for cPARP as a marker of apoptosis, with GAPDH used as a loading control. (E) Representative colony formation images of SK-N-BE(2)-C cells treated with the same combination. Colony formations were quantified and expressed as mean ± SEM relative to vehicle (set to 100%) (n=5).

    Techniques Used: Activity Assay, MTS Assay, Western Blot, Marker, Control



    Similar Products

    93
    MedChemExpress dfmo eflornithine
    (A) SK-N-BE(2)-c cells were treated with five doses of QW-5–70 (0.125 to 2 nM) in combination with five doses of <t>DFMO</t> (10–1000 μM). Cell viability was assessed using the MTS assay (n=4). (B) CI–Fa analysis of the QW-5–70 and DFMO combination. CI values were calculated using the Chou–Talalay median-effect method for five experimentally tested dose pairs at their corresponding Fa values. CI < 1, CI = 1, and CI > 1 indicate synergistic, additive, and antagonistic interactions, respectively. (C) SK-N-BE(2)-c cells were treated with five doses of QW-5–70 (0.125 to 2 nM) in combination with five doses of MLN8237 (1–100 nM). Cell viability was assessed using the MTS assay (n=4). (D) SK-N-BE(2)-C cells were treated with 1 nM QW-5–70 in combination with either DFMO (300 μM, top) or MLN8237 (30 nM, bottom) as indicated. Cell lysates were analyzed by immunoblotting for cPARP as a marker of apoptosis, with GAPDH used as a loading control. (E) Representative colony formation images of SK-N-BE(2)-C cells treated with the same combination. Colony formations were quantified and expressed as mean ± SEM relative to vehicle (set to 100%) (n=5).
    Dfmo Eflornithine, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dfmo eflornithine/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    dfmo eflornithine - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    93
    Selleck Chemicals dfmo
    (A) SK-N-BE(2)-c cells were treated with five doses of QW-5–70 (0.125 to 2 nM) in combination with five doses of <t>DFMO</t> (10–1000 μM). Cell viability was assessed using the MTS assay (n=4). (B) CI–Fa analysis of the QW-5–70 and DFMO combination. CI values were calculated using the Chou–Talalay median-effect method for five experimentally tested dose pairs at their corresponding Fa values. CI < 1, CI = 1, and CI > 1 indicate synergistic, additive, and antagonistic interactions, respectively. (C) SK-N-BE(2)-c cells were treated with five doses of QW-5–70 (0.125 to 2 nM) in combination with five doses of MLN8237 (1–100 nM). Cell viability was assessed using the MTS assay (n=4). (D) SK-N-BE(2)-C cells were treated with 1 nM QW-5–70 in combination with either DFMO (300 μM, top) or MLN8237 (30 nM, bottom) as indicated. Cell lysates were analyzed by immunoblotting for cPARP as a marker of apoptosis, with GAPDH used as a loading control. (E) Representative colony formation images of SK-N-BE(2)-C cells treated with the same combination. Colony formations were quantified and expressed as mean ± SEM relative to vehicle (set to 100%) (n=5).
    Dfmo, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dfmo/product/Selleck Chemicals
    Average 93 stars, based on 1 article reviews
    dfmo - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    93
    MedChemExpress dfmo
    (A) SK-N-BE(2)-c cells were treated with five doses of QW-5–70 (0.125 to 2 nM) in combination with five doses of <t>DFMO</t> (10–1000 μM). Cell viability was assessed using the MTS assay (n=4). (B) CI–Fa analysis of the QW-5–70 and DFMO combination. CI values were calculated using the Chou–Talalay median-effect method for five experimentally tested dose pairs at their corresponding Fa values. CI < 1, CI = 1, and CI > 1 indicate synergistic, additive, and antagonistic interactions, respectively. (C) SK-N-BE(2)-c cells were treated with five doses of QW-5–70 (0.125 to 2 nM) in combination with five doses of MLN8237 (1–100 nM). Cell viability was assessed using the MTS assay (n=4). (D) SK-N-BE(2)-C cells were treated with 1 nM QW-5–70 in combination with either DFMO (300 μM, top) or MLN8237 (30 nM, bottom) as indicated. Cell lysates were analyzed by immunoblotting for cPARP as a marker of apoptosis, with GAPDH used as a loading control. (E) Representative colony formation images of SK-N-BE(2)-C cells treated with the same combination. Colony formations were quantified and expressed as mean ± SEM relative to vehicle (set to 100%) (n=5).
    Dfmo, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dfmo/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    dfmo - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    93
    Tocris difluoromethylornithine
    (A) SK-N-BE(2)-c cells were treated with five doses of QW-5–70 (0.125 to 2 nM) in combination with five doses of <t>DFMO</t> (10–1000 μM). Cell viability was assessed using the MTS assay (n=4). (B) CI–Fa analysis of the QW-5–70 and DFMO combination. CI values were calculated using the Chou–Talalay median-effect method for five experimentally tested dose pairs at their corresponding Fa values. CI < 1, CI = 1, and CI > 1 indicate synergistic, additive, and antagonistic interactions, respectively. (C) SK-N-BE(2)-c cells were treated with five doses of QW-5–70 (0.125 to 2 nM) in combination with five doses of MLN8237 (1–100 nM). Cell viability was assessed using the MTS assay (n=4). (D) SK-N-BE(2)-C cells were treated with 1 nM QW-5–70 in combination with either DFMO (300 μM, top) or MLN8237 (30 nM, bottom) as indicated. Cell lysates were analyzed by immunoblotting for cPARP as a marker of apoptosis, with GAPDH used as a loading control. (E) Representative colony formation images of SK-N-BE(2)-C cells treated with the same combination. Colony formations were quantified and expressed as mean ± SEM relative to vehicle (set to 100%) (n=5).
    Difluoromethylornithine, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/difluoromethylornithine/product/Tocris
    Average 93 stars, based on 1 article reviews
    difluoromethylornithine - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    Image Search Results


    (A) SK-N-BE(2)-c cells were treated with five doses of QW-5–70 (0.125 to 2 nM) in combination with five doses of DFMO (10–1000 μM). Cell viability was assessed using the MTS assay (n=4). (B) CI–Fa analysis of the QW-5–70 and DFMO combination. CI values were calculated using the Chou–Talalay median-effect method for five experimentally tested dose pairs at their corresponding Fa values. CI < 1, CI = 1, and CI > 1 indicate synergistic, additive, and antagonistic interactions, respectively. (C) SK-N-BE(2)-c cells were treated with five doses of QW-5–70 (0.125 to 2 nM) in combination with five doses of MLN8237 (1–100 nM). Cell viability was assessed using the MTS assay (n=4). (D) SK-N-BE(2)-C cells were treated with 1 nM QW-5–70 in combination with either DFMO (300 μM, top) or MLN8237 (30 nM, bottom) as indicated. Cell lysates were analyzed by immunoblotting for cPARP as a marker of apoptosis, with GAPDH used as a loading control. (E) Representative colony formation images of SK-N-BE(2)-C cells treated with the same combination. Colony formations were quantified and expressed as mean ± SEM relative to vehicle (set to 100%) (n=5).

    Journal: Molecular cancer therapeutics

    Article Title: QW-5-70 targets the colchicine site and demonstrates antitumor activity in P-gp–overexpressing cancer models

    doi: 10.1158/1535-7163.MCT-25-1013

    Figure Lengend Snippet: (A) SK-N-BE(2)-c cells were treated with five doses of QW-5–70 (0.125 to 2 nM) in combination with five doses of DFMO (10–1000 μM). Cell viability was assessed using the MTS assay (n=4). (B) CI–Fa analysis of the QW-5–70 and DFMO combination. CI values were calculated using the Chou–Talalay median-effect method for five experimentally tested dose pairs at their corresponding Fa values. CI < 1, CI = 1, and CI > 1 indicate synergistic, additive, and antagonistic interactions, respectively. (C) SK-N-BE(2)-c cells were treated with five doses of QW-5–70 (0.125 to 2 nM) in combination with five doses of MLN8237 (1–100 nM). Cell viability was assessed using the MTS assay (n=4). (D) SK-N-BE(2)-C cells were treated with 1 nM QW-5–70 in combination with either DFMO (300 μM, top) or MLN8237 (30 nM, bottom) as indicated. Cell lysates were analyzed by immunoblotting for cPARP as a marker of apoptosis, with GAPDH used as a loading control. (E) Representative colony formation images of SK-N-BE(2)-C cells treated with the same combination. Colony formations were quantified and expressed as mean ± SEM relative to vehicle (set to 100%) (n=5).

    Article Snippet: Paclitaxel was purchased from LC Laboratories; colchicine and verapamil from Sigma; and Q-VD-OPh (QVD), tariquidar, DFMO (eflornithine), and MLN8237 from MedChemExpress.

    Techniques: Activity Assay, MTS Assay, Western Blot, Marker, Control